Loading...
•
Sep 30, 2024
Cue Biopharma Q3 2024 Earnings Report
Reported an increase in collaboration revenue driven by the Ono Collaboration, while also seeing decreases in research and development, and general and administrative expenses.
Key Takeaways
Cue Biopharma reported its Q3 2024 financial results, featuring increased collaboration revenue and reduced research and development, and general and administrative expenses. The company highlighted positive updated data from Phase 1 trials of CUE-101 and CUE-102, along with the advancement of preclinical programs.
Collaboration revenue increased by $1.2 million to $3.3 million due to the Ono Collaboration.
Research and development expenses decreased by $0.5 million to $9.4 million.
General and administrative expenses decreased by $0.7 million to $2.9 million.
Cash and cash equivalents totaled $32.4 million as of September 30, 2024.
Cue Biopharma
Cue Biopharma
Cue Biopharma Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Cue Biopharma expects its current cash and cash equivalents to fund operations into the fourth quarter of 2025.